Photodynamic therapy in superficial bladder cancer: Past, present and future

Urological Research

Volumn 29, Issue 6, 2001, Pages 396-405

  Jichlinski, P ^a   Leisinger, H J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Bladder cancer; Dihaematoporphyrin derivatives; Hexyl ester of aminolevulinic acid; Hypericin; Photodynamic therapy; Protoporphyrin IX 5 aminolevulinic acid

Indexed keywords

AMINOLEVULINIC ACID; BACTERIOCHLORIN; BENZOPORPHYRIN DERIVATIVE; HYPERICIN; PHTHALOCYANINE DERIVATIVE; PROTOPORPHYRIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER RECURRENCE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CORRELATION ANALYSIS; HUMAN; LIGHT ABSORPTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SUPERFICIAL CANCER; TREATMENT INDICATION; TREATMENT OUTCOME;

HUMANS; PHOTOCHEMOTHERAPY; URINARY BLADDER NEOPLASMS;

EID: 0035675068     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002400100215     Document Type: Review

References (100)

1. New drugs and future developments in photodynamic therapy
2. Comparison of intravenous and intravesical administration of chloro-aluminum sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model
3. Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer
4. Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells
5. The use of lipid emulsion as an intravesical medium to disperse light in the potential treatment of bladder tumors
6. In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer
7. Treatment of bladder cancer with hematoporphyrin derivatives and laser light
8. Detection and localization of in situ carcinoma of the bladder with hematoporphyrin derivative
9. Systems for light application and dosimetry in photodynamic therapy
10. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer
11. Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid
12. Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: Light diffusion and histological changes
13. A review of the optical properties of biological tissues
14. Genetic errors, cell proliferation, and carcinogenesis
15. Photodynamic therapy of bladder cancer cell lines
16. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line
17. Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder
18. Initial evaluation of whole bladder wall photodynamic therapy after intravesical ALA sensitization for carcinoma in situ of the bladder
19. Fluorescence detection of flat carcinoma in situ of the bladder after intravesical instillation with ALA
20. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin
21. Photosensitizers: Therapy and detection of malignant tumors
22. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages
23. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity
24. Fluorescence excitation and emission spectra of ALA induced protoporphyrin IX in normal and tumoral tissue of the human bladder
25. Complications of whole bladder dihematoporphyrin ether photodynamic therapy
26. How does photodynamic therapy work?
27. Hemodynamic effects of 5-aminolevulinic acid in humans
28. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients
29. A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin
30. Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model
31. In vivo fluence rate and fractionation effects on tumor response and photobleaching: Photodynamic therapy with two photosensitizers in an orthotopic rat tumor model
32. Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid
33. Clinical assessment of fluorescence cystoscopy during transurethral bladder resection in superficial bladder cancer
34. First report on hexyl-ester aminolevulinic acid (h-ALA) induced fluorescence cystoscopy in superficial bladder cancer
35. Clinical experience with the integral photodynamic therapy of bladder carcinoma
36. Photodynamic therapy of bladder carcinoma
37. Factors controlling the selectivity and efficiency of tumour damage in photodynamic therapy
38. Photodynamic activity of hypericin in human urinary bladder carcinoma cells
39. Hematoporphyrin derivative: A possible aid in the diagnosis and therapy of carcinoma of the bladder
40. Photodynamic therapy with endogenous Protoporphyrin IX: Basic principles and present clinical experience
41. Endogenous protoporphyrin IX, a clinical useful photosensitizer for photodynamic therapy
42. Prodrugs of 5-aminolevulinic acid for photodynamic therapy
43. Possible advantages of aluminum-chloro-tetrasulfonated phthalocyanine over hematoporphyrin derivative as a photosensitizer in photodynamic therapy
44. Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors
45. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro
46. Photodynamic diagnosis following topical application of delta-aminolevulinic acid in a rat tumor model
47. Integral photodynamic treatment of refractory superficial bladder cancer
48. A detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence
49. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer
50. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a EORTC randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone
51. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX: A pilot study
52. Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia
53. Kinetics of endogenous protoporphyrin IX induction by aminolevulinic acid: Preliminary studies in the bladder
54. Subcellular phototoxicity of 5-aminolevulinic acid (ALA)
55. Photodynamic therapy, development of a treatment system adapted to superficial tumours of the bladder
56. Photodynamic therapy for superficial bladder carcinoma
57. Photodynamic therapy (PDT) and Photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): Current clinical and development status
58. Treatment system for whole bladder wall photodynamic therapy with in vivo monitoring and control of light dose rate and dose
59. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: An in vitro approach
60. In vivo photosensitization of urothelial bladder carcinoma with aminolevulic acid or hexylester of aminolevulinic acid induced protorphyrin IX
61. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: Implications for photodynamic treatment
62. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder
63. The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer
64. Photodynamic effects of sulfonated aluminum chlorophthalocyanine in human urinary bladder carcinoma cells in vitro
65. Apoptosis and necrosis induced with light and 5-aminolevulinic acid-derived protoporphyrin IX
66. Whole bladder photodynamic therapy: Critical review of present-day technology and rationale for development of intravesical laser catheter and monitoring system
67. Urinary cytokines following photodynamic therapy for bladder cancer: A preliminary report
68. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder
69. Photophysical and photobiological processes in the photodynamic therapy of tumours
70. Photodynamic therapy in oncology: Mechanisms and clinical use
71. 5-Aminolevulinic acid-based photodynamic therapy: Principles and experimental research
72. Photodynamic therapy
73. A comparison of functional bladder damage after intravesical photodynamic therapy with three different photosensitizers
74. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder
75. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis
76. A compilation of singlet oxygen yields from biologically relevant molecules
77. Photosensitization and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX - A pilot study
78. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood
79. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer
80. Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells in vitro
81. Dynamic fluorescence changes during photodynamic therapy in vivo and in vitro of hydrophilic A1 (III) phthalocyanine tetrasulphonate and lipophilic Zn (II) phthalocyanine administered in liposomes
82. Light penetration in bladder tissue: Implications for the intravesical photodynamic therapy of bladder tumours
83. The use of photodynamic therapy (PDT) for the treatment of superficial tumours on the bladder wall
84. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers
85. Integrating sphere effect in whole-bladder-wall photodynamic therapy: III. Fluence multiplication, optical penetration and light distribution with an eccentric source for human bladder optical properties
86. Intravesical instillation of 5-aminolevulinic acid: The fluorescent metabolite is limited to urothelial cells
87. Cellular fluorescence of the endogenous photosensitiser protoporphyrin IX following exposure to 5-aminolevulinic acid
88. Electromotive diffusion (EMD) and photodynamic therapy with delta-aminolevulinic acid (ALA) for superficial bladder cancer
89. Wavelength dependent photodynamic effects on chemically induced rat bladder tumors following intravesical instillation of 5-aminolevulinic acid
90. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitisation and laser irradiation
91. Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder
92. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors
93. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer
94. Two years' experience with photodynamic therapy of bladder carcinoma
95. Factors affecting aminolevulinic acid-induced generation of protoporphyrin IX
96. The influence of hypoxia and pH on amimolevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro
97. Cell cycle phase influence tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro
98. Feasibility of photodynamic endometrial ablation without anesthesia
99. Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: Implications for photodynamic therapy
100. Effect of delivery system on the pharmacokinetics and tissue distribution of bis (di-isobutyl octadecylsiloxy) silicon 2, 3-naphthalocyanine (isoBOSINC), a photosensitizer for tumor therapy